Mozavaptan (BioDeep_00000181110)
human metabolite blood metabolite
代谢物信息卡片
N-{4-[5-(dimethylamino)-2,3,4,5-tetrahydro-1H-1-benzazepine-1-carbonyl]phenyl}-2-methylbenzamide
化学式: C27H29N3O2 (427.2259654)
中文名称: 莫扎伐坦
谱图信息:
最多检出来源 Homo sapiens(blood) 99.54%
分子结构信息
SMILES: CC1=CC=CC=C1C(=O)NC2=CC=C(C=C2)C(=O)N3CCCC(C4=CC=CC=C43)N(C)C
InChI: InChI=1S/C27H29N3O2/c1-19-9-4-5-10-22(19)26(31)28-21-16-14-20(15-17-21)27(32)30-18-8-13-24(29(2)3)23-11-6-7-12-25(23)30/h4-7,9-12,14-17,24H,8,13,18H2,1-3H3,(H,28,31)
描述信息
C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist > C2180 - Vasopressin Antagonist
D045283 - Natriuretic Agents > D065092 - Antidiuretic Hormone Receptor Antagonists
D002317 - Cardiovascular Agents > D045283 - Natriuretic Agents
同义名列表
数据库引用编号
5 个数据库交叉引用编号
- ChEBI: CHEBI:135694
- PubChem: 119369
- HMDB: HMDB0254910
- ChEMBL: CHEMBL420762
- CAS: 137975-06-5
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Tareq B Malas, Wytze J Vlietstra, Roman Kudrin, Sergey Starikov, Mohammed Charrout, Marco Roos, Dorien J M Peters, Jan A Kors, Rein Vos, Peter A C 't Hoen, Erik M van Mulligen, Kristina M Hettne. Drug prioritization using the semantic properties of a knowledge graph.
Scientific reports.
2019 04; 9(1):6281. doi:
10.1038/s41598-019-42806-6. [PMID: 31000794] - Essam Ezzeldin, Gamal Ae Mostafa, Muzaffar Iqbal, Khalid A Al-Rashood, Yousef Asiri, Toqa El-Nahhas. UPLC/MS-MS assay development for estimation of mozavaptan in plasma and its pharmacokinetic study in rats.
Bioanalysis.
2018 Jul; 10(14):1077-1086. doi:
10.4155/bio-2018-0092. [PMID: 29745750] - Mareike Franke, Bettina Baeßler, Jan Vechtel, Claudia Dafinger, Martin Höhne, Lori Borgal, Heike Göbel, Friederike Koerber, David Maintz, Thomas Benzing, Bernhard Schermer, Thorsten Persigehl. Magnetic resonance T2 mapping and diffusion-weighted imaging for early detection of cystogenesis and response to therapy in a mouse model of polycystic kidney disease.
Kidney international.
2017 12; 92(6):1544-1554. doi:
10.1016/j.kint.2017.05.024. [PMID: 28754558] - Debbie Zittema, Irina B Versteeg, Ron T Gansevoort, Harry van Goor, Emile de Heer, Kimberley A M Veraar, Dorien J M Peters, Esther Meijer. Dose-Titrated Vasopressin V2 Receptor Antagonist Improves Renoprotection in a Mouse Model for Autosomal Dominant Polycystic Kidney Disease.
American journal of nephrology.
2016; 44(3):194-203. doi:
10.1159/000448693. [PMID: 27578560] - Yasukatsu Izumi, Katsuyuki Miura, Hiroshi Iwao. Therapeutic potential of vasopressin-receptor antagonists in heart failure.
Journal of pharmacological sciences.
2014; 124(1):1-6. doi:
10.1254/jphs.13r13cp. [PMID: 24401675] - Tetsuo Tamura, Kazuo Takeuchi. Small cell gall bladder carcinoma complicated by syndrome of inappropriate secretion of antidiuretic hormone (SIADH) treated with mozavaptan.
BMJ case reports.
2013 Jun; 2013(?):. doi:
10.1136/bcr-2013-010039. [PMID: 23761568] - Kazuhiro Takahashi, Noriko Makita, Katsunori Manaka, Masataka Hisano, Yuko Akioka, Kenichiro Miura, Noriyuki Takubo, Atsuko Iida, Norishi Ueda, Makiko Hashimoto, Toshiro Fujita, Takashi Igarashi, Takashi Sekine, Taroh Iiri. V2 vasopressin receptor (V2R) mutations in partial nephrogenic diabetes insipidus highlight protean agonism of V2R antagonists.
The Journal of biological chemistry.
2012 Jan; 287(3):2099-106. doi:
10.1074/jbc.m111.268797. [PMID: 22144672] - E Meijer, R T Gansevoort, P E de Jong, A M van der Wal, W N Leonhard, S R de Krey, J van den Born, G M Mulder, H van Goor, J Struck, E de Heer, D J M Peters. Therapeutic potential of vasopressin V2 receptor antagonist in a mouse model for autosomal dominant polycystic kidney disease: optimal timing and dosing of the drug.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
2011 Aug; 26(8):2445-53. doi:
10.1093/ndt/gfr069. [PMID: 21393612] - Olivier Devuyst, Xueqi Wang, Andreas Serra. Vasopressin-2 receptor antagonists in autosomal dominant polycystic kidney disease: from man to mouse and back.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
2011 Aug; 26(8):2423-5. doi:
10.1093/ndt/gfr380. [PMID: 21803730] - Carles Villabona. [Vasopressin receptor antagonists: the vaptans].
Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion.
2010 May; 57 Suppl 2(?):41-52. doi:
10.1016/s1575-0922(10)70021-8. [PMID: 21130961] - Taizo Takeda, Setsuko Takeda, Akinobu Kakigi, Teruhiko Okada, Rie Nishioka, Daizo Taguchi, Masahiko Nishimura, Hiroaki Nakatani. Hormonal aspects of Ménière's disease on the basis of clinical and experimental studies.
ORL; journal for oto-rhino-laryngology and its related specialties.
2010; 71 Suppl 1(?):1-9. doi:
10.1159/000265113. [PMID: 20185943] - Peter Bie, Simon Mølstrøm, Søren Wamberg. Normotensive sodium loading in conscious dogs: regulation of renin secretion during beta-receptor blockade.
American journal of physiology. Regulatory, integrative and comparative physiology.
2009 Feb; 296(2):R428-35. doi:
10.1152/ajpregu.90753.2008. [PMID: 19073902] - Vicente E Torres. Role of vasopressin antagonists.
Clinical journal of the American Society of Nephrology : CJASN.
2008 Jul; 3(4):1212-8. doi:
10.2215/cjn.05281107. [PMID: 18434616] - Sho Maejima, Toshiki Yamada, Takayuki Hamada, Kouhei Matsuda, Minoru Uchiyama. Effects of hypertonic stimuli and arginine vasotocin (AVT) on water absorption response in Japanese treefrog, Hyla japonica.
General and comparative endocrinology.
2008 Jun; 157(2):196-202. doi:
10.1016/j.ygcen.2008.04.014. [PMID: 18555070] - A H Molnár, C Varga, A Berkó, I Rojik, A Párducz, F László, F A László. Inhibitory effect of vasopressin receptor antagonist OPC-31260 on experimental brain oedema induced by global cerebral ischaemia.
Acta neurochirurgica.
2008 Mar; 150(3):265-71. doi:
10.1007/s00701-007-1400-1. [PMID: 18288441] - Andor H Molnár, Csaba Varga, Anikó Berkó, Imre Rojik, Arpád Párducz, Ferenc László, Ferenc A László. Prevention of hypoxic brain oedema by the administration of vasopressin receptor antagonist OPC-31260.
Progress in brain research.
2008; 170(?):519-25. doi:
10.1016/s0079-6123(08)00439-1. [PMID: 18655905] - Niels Hadrup, Jørgen S Petersen, Søren Windfeld, Lotte Risom, Claus B Andersen, Søren Nielsen, Sten Christensen, Thomas E N Jonassen. Differential down-regulation of aquaporin-2 in rat kidney zones by peripheral nociceptin/orphanin FQ receptor agonism and vasopressin type-2 receptor antagonism.
The Journal of pharmacology and experimental therapeutics.
2007 Nov; 323(2):516-24. doi:
10.1124/jpet.107.123588. [PMID: 17693587] - Paul M O'Connor, Allen W Cowley. Vasopressin-induced nitric oxide production in rat inner medullary collecting duct is dependent on V2 receptor activation of the phosphoinositide pathway.
American journal of physiology. Renal physiology.
2007 Aug; 293(2):F526-32. doi:
10.1152/ajprenal.00052.2007. [PMID: 17507604] - Andor H Molnár, Csaba Varga, Tamás Janáky, Gábor Tóth, Géza Tóth, Judit Farkas, Ferenc László, Ferenc A László. Biological half-life and organ distribution of [3H]8-arginine vasopressin following administration of vasopressin receptor antagonist OPC-31260.
Regulatory peptides.
2007 Jun; 141(1-3):12-8. doi:
10.1016/j.regpep.2006.12.011. [PMID: 17258819] - Itsuro Kazama, Tomohiro Arata, Mari Michimata, Ryo Hatano, Michiko Suzuki, Noriyuki Miyama, Satoru Sanada, Akira Sato, Susumu Satomi, Yutaka Ejima, Sei Sasaki, Mitsunobu Matsubara. Lithium effectively complements vasopressin V2 receptor antagonist in the treatment of hyponatraemia of SIADH rats.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
2007 Jan; 22(1):68-76. doi:
10.1093/ndt/gfl110. [PMID: 16702208] - Eiji Higashihara. [Polycystic kidney disease].
Nihon Jinzo Gakkai shi.
2007; Suppl 50th Ann(?):83-90. doi:
NULL. [PMID: 17899832] - Marta Martín-Llahí, Mónica Guevara, Pere Ginès. Hyponatremia in cirrhosis: clinical features and management.
Gastroenterologie clinique et biologique.
2006 Oct; 30(10):1144-51. doi:
10.1016/s0399-8320(06)73492-3. [PMID: 17075468] - Otto Fröhlich, Janet D Klein, Pauline M Smith, Jeff M Sands, Robert B Gunn. Regulation of UT-A1-mediated transepithelial urea flux in MDCK cells.
American journal of physiology. Cell physiology.
2006 Oct; 291(4):C600-6. doi:
10.1152/ajpcell.00413.2005. [PMID: 16641165] - Taizo Takeda, Setsuko Takeda, Akinobu Kakigi, Teruhiko Okada, Rie Nishioka, Daizo Taguchi. A comparison of dehydration effects of V2-antagonist (OPC-31260) on the inner ear between systemic and round window applications.
Hearing research.
2006 Aug; 218(1-2):89-97. doi:
10.1016/j.heares.2006.05.001. [PMID: 16781097] - Weidong Wang, Chunling Li, Sandra N Summer, Sandor Falk, Melissa A Cadnapaphornchai, Yung-Chang Chen, Robert W Schrier. Molecular analysis of impaired urinary diluting capacity in glucocorticoid deficiency.
American journal of physiology. Renal physiology.
2006 May; 290(5):F1135-42. doi:
10.1152/ajprenal.00356.2005. [PMID: 16352742] - Masayuki Takeuchi, Jong-Dae Lee, Hiromasa Shimizu, Takanori Ueda. Effects of long-term oral treatment with selective vasopressin V2 receptor antagonist (OPC-31260) on adriamycin-induced heart failure in rats.
International journal of cardiology.
2006 Apr; 108(2):231-6. doi:
10.1016/j.ijcard.2005.05.009. [PMID: 16002161] - Itsuro Kazama, Ryo Hatano, Mari Michimata, Katsuya Suzuki, Tomohiro Arata, Michiko Suzuki, Noriyuki Miyama, Akira Sato, Susumu Satomi, Yutaka Ejima, Sei Sasaki, Mitsunobu Matsubara. BSC1 inhibition complements effects of vasopressin V2 receptor antagonist on hyponatremia in SIADH rats.
Kidney international.
2005 May; 67(5):1855-67. doi:
10.1111/j.1523-1755.2005.00284.x. [PMID: 15840033] - Xiaofang Wang, Vincent Gattone, Peter C Harris, Vicente E Torres. Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat.
Journal of the American Society of Nephrology : JASN.
2005 Apr; 16(4):846-51. doi:
10.1681/asn.2004121090. [PMID: 15728778] - Michele Buemi, Lorena Nostro, Giuseppe Di Pasquale, Emanuela Cavallaro, Alessio Sturiale, Fulvio Floccari, Carmela Aloisi, Antonella Ruello, Gioacchino Calapai, Francesco Corica, Nicola Frisina. Aquaporin-2 water channels in spontaneously hypertensive rats.
American journal of hypertension.
2004 Dec; 17(12 Pt 1):1170-8. doi:
10.1016/j.amjhyper.2004.07.003. [PMID: 15607625] - Sheila A Doggrell. Do vasopressin receptor type 2 antagonists have therapeutic potential in polycystic kidney diseases?.
Expert opinion on investigational drugs.
2004 Apr; 13(4):431-4. doi:
10.1517/13543784.13.4.431. [PMID: 15102592] - Vicente E Torres, Xiaofang Wang, Qi Qian, Stefan Somlo, Peter C Harris, Vincent H Gattone. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease.
Nature medicine.
2004 Apr; 10(4):363-4. doi:
10.1038/nm1004. [PMID: 14991049] - Vincent H Gattone, Xiaofang Wang, Peter C Harris, Vicente E Torres. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist.
Nature medicine.
2003 Oct; 9(10):1323-6. doi:
10.1038/nm935. [PMID: 14502283] - James Walter Ferguson, George Therapondos, David E Newby, Peter Clive Hayes. Therapeutic role of vasopressin receptor antagonism in patients with liver cirrhosis.
Clinical science (London, England : 1979).
2003 Jul; 105(1):1-8. doi:
10.1042/cs20030062. [PMID: 12639215] - K Shimizu. Combined effects of vasopressin V2 receptor antagonist and loop diuretic in humans.
Clinical nephrology.
2003 Mar; 59(3):164-73. doi:
10.5414/cnp59164. [PMID: 12653258] - Shoshiro Okada, Yoshinori Murakami, Kumiko Nakamura, Kunihiko Yokotani. Vasopressin V(1) receptor-mediated activation of central sympatho-adrenomedullary outflow in rats.
European journal of pharmacology.
2002 Dec; 457(1):29-35. doi:
10.1016/s0014-2999(02)02652-3. [PMID: 12460640] - H Yokoi, H Nagasaki, K Tachikawa, H Arima, T Murase, Y Miura, M Hirabayashi, Y Oiso. Adaptation to sustained high plasma vasopressin in water and electrolyte homeostasis in the rat transgenic for the metallothionein-vasopressin fusion gene.
The Journal of endocrinology.
2002 Apr; 173(1):23-33. doi:
10.1677/joe.0.1730023. [PMID: 11927381] - Claudia A Bertuccio, Fernando R Ibarra, Jorge E Toledo, Elvira E Arrizurieta, Rodolfo S Martin. Endogenous vasopressin regulates Na-K-ATPase and Na(+)-K(+)-Cl(-) cotransporter rbsc-1 in rat outer medulla.
American journal of physiology. Renal physiology.
2002 Feb; 282(2):F265-70. doi:
10.1152/ajprenal.00354.2000. [PMID: 11788440] - Dennis Staahltoft, Søren Nielsen, Nadeem R Janjua, Sten Christensen, Ole Skøtt, Niels Marcussen, Thomas E N Jonassen. Losartan treatment normalizes renal sodium and water handling in rats with mild congestive heart failure.
American journal of physiology. Renal physiology.
2002 Feb; 282(2):F307-15. doi:
10.1152/ajprenal.00132.2001. [PMID: 11788445] - N R Janjua, T E Jonassen, S Langhoff, K Thomsen, S Christensen. Role of sodium depletion in acute antidiuretic effect of bendroflumethiazide in rats with nephrogenic diabetes insipidus.
The Journal of pharmacology and experimental therapeutics.
2001 Oct; 299(1):307-13. doi:
NULL. [PMID: 11561093] - I M Lankhuizen, R van Veghel, P R Saxena, R G Schoemaker. Vascular and renal effects of vasopressin and its antagonists in conscious rats with chronic myocardial infarction; evidence for receptor shift.
European journal of pharmacology.
2001 Jul; 423(2-3):195-202. doi:
10.1016/s0014-2999(01)01092-5. [PMID: 11448485] - L M Fleeman, P J Irwin, P A Phillips, J West. Effects of an oral vasopressin receptor antagonist (OPC-31260) in a dog with syndrome of inappropriate secretion of antidiuretic hormone.
Australian veterinary journal.
2000 Dec; 78(12):825-30. doi:
10.1111/j.1751-0813.2000.tb10497.x. [PMID: 11194468] - C Serradeil-Le Gal, D Raufaste, E Double-Cazanave, G Guillon, C Garcia, M Pascal, J P Maffrand. Binding properties of a selective tritiated vasopressin V2 receptor antagonist, [H]-SR 121463.
Kidney international.
2000 Oct; 58(4):1613-22. doi:
10.1046/j.1523-1755.2000.00322.x. [PMID: 11012895] - I M Lankhuizen, R van Veghel, P R Saxena, R G Schoemaker. [Arg8]-vasopressin-induced responses on coronary and mesenteric arteries of rats with myocardial infarction: the effects of V1a- and V2-receptor antagonists.
Journal of cardiovascular pharmacology.
2000 Jul; 36(1):38-44. doi:
10.1097/00005344-200007000-00005. [PMID: 10892658] - Y Nakamura, T Haneda, J Osaki, S Miyata, K Kikuchi. Hypertrophic growth of cultured neonatal rat heart cells mediated by vasopressin V(1A) receptor.
European journal of pharmacology.
2000 Mar; 391(1-2):39-48. doi:
10.1016/s0014-2999(99)00775-x. [PMID: 10720633] - A B Roald, O Tenstad, K Aukland. The effect of AVP-V2 receptor stimulation on local GFR in the rat kidney.
Acta physiologica Scandinavica.
2000 Feb; 168(2):351-9. doi:
10.1046/j.1365-201x.2000.00663.x. [PMID: 10712572] - A Naito, Y Ohtake, H Hasegaw, A Y Fukaya, T Kurasawa, K Naito, H Matsukawa, T Oguma, Y Ezure, Y Tsuriya, H Tanaka, K Koike, K Shigenobu. Pharmacological profile of VP-343, a novel selective vasopressin V2 receptor antagonist, in rats.
Biological & pharmaceutical bulletin.
2000 Feb; 23(2):182-9. doi:
10.1248/bpb.23.182. [PMID: 10706381] - B M Christensen, M Zelenina, A Aperia, S Nielsen. Localization and regulation of PKA-phosphorylated AQP2 in response to V(2)-receptor agonist/antagonist treatment.
American journal of physiology. Renal physiology.
2000 Jan; 278(1):F29-42. doi:
10.1152/ajprenal.2000.278.1.f29. [PMID: 10644653] - M Bosch-Marcé, J L Poo, W Jiménez, N Bordas, A Leivas, M Morales-Ruiz, R M Muñoz, M Pérez, V Arroyo, F Rivera, J Rodés. Comparison of two aquaretic drugs (niravoline and OPC-31260) in cirrhotic rats with ascites and water retention.
The Journal of pharmacology and experimental therapeutics.
1999 Apr; 289(1):194-201. doi:
NULL. [PMID: 10087004] - F A László, C Varga, S Nakamura. Vasopressin receptor antagonist OPC-31260 prevents cerebral oedema after subarachnoid haemorrhage.
European journal of pharmacology.
1999 Jan; 364(2-3):115-22. doi:
10.1016/s0014-2999(98)00836-x. [PMID: 9932713] - V H Gattone, R L Maser, C Tian, J M Rosenberg, M G Branden. Developmental expression of urine concentration-associated genes and their altered expression in murine infantile-type polycystic kidney disease.
Developmental genetics.
1999; 24(3-4):309-18. doi:
10.1002/(sici)1520-6408(1999)24:3/4<309::aid-dvg14>3.0.co;2-5. [PMID: 10322639] - Y Yamamura, S Nakamura, S Itoh, T Hirano, T Onogawa, T Yamashita, Y Yamada, K Tsujimae, M Aoyama, K Kotosai, H Ogawa, H Yamashita, K Kondo, M Tominaga, G Tsujimoto, T Mori. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats.
The Journal of pharmacology and experimental therapeutics.
1998 Dec; 287(3):860-7. doi:
NULL. [PMID: 9864265] - B Dolgor, S Kitano, T Yoshida, T Bandoh, K Ninomiya, T Matsumoto. Vasopressin antagonist improves renal function in a rat model of pneumoperitoneum.
The Journal of surgical research.
1998 Oct; 79(2):109-14. doi:
10.1006/jsre.1998.5409. [PMID: 9758724] - D Marples, B M Christensen, J Frokiaer, M A Knepper, S Nielsen. Dehydration reverses vasopressin antagonist-induced diuresis and aquaporin-2 downregulation in rats.
The American journal of physiology.
1998 09; 275(3):F400-9. doi:
10.1152/ajprenal.1998.275.3.f400. [PMID: 9729513] - B M Christensen, D Marples, U B Jensen, J Frokiaer, D Sheikh-Hamad, M Knepper, S Nielsen. Acute effects of vasopressin V2-receptor antagonist on kidney AQP2 expression and subcellular distribution.
The American journal of physiology.
1998 08; 275(2):F285-97. doi:
10.1152/ajprenal.1998.275.2.f285. [PMID: 9691020] - T E Jonassen, S Nielsen, S Christensen, J S Petersen. Decreased vasopressin-mediated renal water reabsorption in rats with compensated liver cirrhosis.
The American journal of physiology.
1998 08; 275(2):F216-25. doi:
10.1152/ajprenal.1998.275.2.f216. [PMID: 9691010] - J D Albright, M F Reich, E G Delos Santos, J P Dusza, F W Sum, A M Venkatesan, J Coupet, P S Chan, X Ru, H Mazandarani, T Bailey. 5-Fluoro-2-methyl-N-[4-(5H-pyrrolo[2,1-c]-[1, 4]benzodiazepin-10(11H)-ylcarbonyl)-3-chlorophenyl]benzamide (VPA-985): an orally active arginine vasopressin antagonist with selectivity for V2 receptors.
Journal of medicinal chemistry.
1998 Jul; 41(14):2442-4. doi:
10.1021/jm980179c. [PMID: 9651149] - L M Burrell, P A Phillips, J Risvanis, R K Chan, K L Aldred, C I Johnston. Long-term effects of nonpeptide vasopressin V2 antagonist OPC-31260 in heart failure in the rat.
The American journal of physiology.
1998 07; 275(1):H176-82. doi:
10.1152/ajpheart.1998.275.1.h176. [PMID: 9688911] - L Grove, P Christensen, P Bie. Effects of receptor blockade on metabolism and renal actions of vasopressin in conscious dogs.
Acta physiologica Scandinavica.
1998 May; 163(1):93-101. doi:
10.1046/j.1365-201x.1998.00332.x. [PMID: 9648627] - T Inoue, A Ohnishi, A Matsuo, B Kawai, N Kunihiro, Y Tada, F Koizumi, T Chau, K Okada, Y Yamamura, T Tanaka. Therapeutic and diagnostic potential of a vasopressin-2 antagonist for impaired water handling in cirrhosis.
Clinical pharmacology and therapeutics.
1998 May; 63(5):561-70. doi:
10.1016/s0009-9236(98)90107-2. [PMID: 9630829] - M Ohara, P Y Martin, D L Xu, J St John, T A Pattison, J K Kim, R W Schrier. Upregulation of aquaporin 2 water channel expression in pregnant rats.
The Journal of clinical investigation.
1998 Mar; 101(5):1076-83. doi:
10.1172/jci649. [PMID: 9486978] - C Czaplewski, R Kaźmierkiewicz, J Ciarkowski. Molecular modelling of the vasopressin V2 receptor/antagonist interactions.
Acta biochimica Polonica.
1998; 45(1):19-26. doi:
10.18388/abp.1998_4314. [PMID: 9701492] - M Naitoh, J Power, P A Phillips, J Risvanis, C I Johnston, L M Burrell. Effects of chronic AVP V2R blockade in congestive heart failure in sheep. Comparison with chronic ACE inhibition.
Advances in experimental medicine and biology.
1998; 449(?):445-6. doi:
10.1007/978-1-4615-4871-3_56. [PMID: 10026836] - S Ishikawa, T Saito, N Fujita, S Sasaki, F Marumo, T Saito. Expression and subcellular localization of water channel aquaporin-2 in conscious rats.
Kidney international. Supplement.
1997 Oct; 61(?):S6-9. doi:
NULL. [PMID: 9328954] - C Kitiyakara, C S Wilcox. Vasopressin V2-receptor antagonists: panaceas for hyponatremia?.
Current opinion in nephrology and hypertension.
1997 Sep; 6(5):461-7. doi:
10.1097/00041552-199709000-00009. [PMID: 9327205] - J Hensen, M Buchfelder, P Gross. [Aquaretic drugs--a new therapeutic principle in treatment of hyponatremia?].
Fortschritte der Medizin.
1997 Jun; 115(17):46-50. doi:
NULL. [PMID: 9312543] - D L Xu, P Y Martin, M Ohara, J St John, T Pattison, X Meng, K Morris, J K Kim, R W Schrier. Upregulation of aquaporin-2 water channel expression in chronic heart failure rat.
The Journal of clinical investigation.
1997 Apr; 99(7):1500-5. doi:
10.1172/jci119312. [PMID: 9119993] - T Saito, S Ishikawa, K Abe, K Kamoi, K Yamada, K Shimizu, T Saruta, S Yoshida. Acute aquaresis by the nonpeptide arginine vasopressin (AVP) antagonist OPC-31260 improves hyponatremia in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH).
The Journal of clinical endocrinology and metabolism.
1997 Apr; 82(4):1054-7. doi:
10.1210/jcem.82.4.3900. [PMID: 9100572] - M Naitoh, L M Burrell, J Risvanis, K L Aldred, M D Rockell, C I Johnston, P A Phillips. Modulation of genetic hypertension by short-term AVP V1A or V2 receptor antagonism in young SHR.
The American journal of physiology.
1997 Feb; 272(2 Pt 2):F229-34. doi:
10.1152/ajprenal.1997.272.2.f229. [PMID: 9124400] - K Kamoi. Syndrome of inappropriate antidiuresis without involving inappropriate secretion of vasopressin in an elderly woman: effect of intravenous administration of the nonpeptide vasopressin V2 receptor antagonist OPC-31260.
Nephron.
1997; 76(1):111-5. doi:
10.1159/000190149. [PMID: 9171309] - Y Mimura, T Ogura, N Hayakawa, F Otsuka, M Hashimoto, T Yamauchi, H Makino, N Ogawa. In vitro macro- and microautoradiographic localization of V1 and V2 receptors in the rat kidney using OPC-21268 and OPC-31260.
Nephron.
1997; 76(3):331-6. doi:
10.1159/000190200. [PMID: 9226235] - Y Hirata, H Hayakawa, M Kakoki, A Tojo, E Suzuki, D Nagata, K Kimura, A Goto, K Kikuchi, T Nagano, M Hirobe, M Omata. Receptor subtype for vasopressin-induced release of nitric oxide from rat kidney.
Hypertension (Dallas, Tex. : 1979).
1997 Jan; 29(1 Pt 1):58-64. doi:
10.1161/01.hyp.29.1.58. [PMID: 9039081] - C Serradeil-Le Gal, C Lacour, G Valette, G Garcia, L Foulon, G Galindo, L Bankir, B Pouzet, G Guillon, C Barberis, D Chicot, S Jard, P Vilain, C Garcia, E Marty, D Raufaste, G Brossard, D Nisato, J P Maffrand, G Le Fur. Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist.
The Journal of clinical investigation.
1996 Dec; 98(12):2729-38. doi:
10.1172/jci119098. [PMID: 8981918] - M Bosch-Marcé, J Clària, W Jiménez. [Aquaretic agents].
Gastroenterologia y hepatologia.
1996 Nov; 19(9):472-7. doi:
NULL. [PMID: 8998673] - T Saito. SIADH and other hyponatremic disorders: diagnosis and therapeutic problems.
Nihon Jinzo Gakkai shi.
1996 Oct; 38(10):429-34. doi:
NULL. [PMID: 8940823] - C Kunick, A Link, M Hropot. Synthesis and in vivo testing of a potential aquaretic agent.
Die Pharmazie.
1996 Aug; 51(8):601-2. doi:
NULL. [PMID: 8794472] - K Yoshitomi, M Naruse, K Hanaoka, Y Yamamura, M Imai, K Kurokawa. Functional characterization of vasopressin V1 and V2 receptors in the rabbit renal cortical collecting duct.
Kidney international. Supplement.
1996 Jun; 55(?):S177-82. doi:
NULL. [PMID: 8743549] - H W Liu, Y X Wang, J T Crofton, T Funyu, L Share. Central vasopressin blockade enhances its peripheral release in response to peripheral osmotic stimulation in conscious rats.
Brain research.
1996 May; 719(1-2):14-22. doi:
10.1016/0006-8993(96)00054-6. [PMID: 8782858] - T Nishikimi, Y Kawano, Y Saito, H Matsuoka. Effect of long-term treatment with selective vasopressin V1 and V2 receptor antagonist on the development of heart failure in rats.
Journal of cardiovascular pharmacology.
1996 Feb; 27(2):275-82. doi:
10.1097/00005344-199602000-00015. [PMID: 8720428] - Y Imai, C Y Kim, J Hashimoto, N Minami, M Munakata, K Abe. Role of vasopressin in neurocardiogenic responses to hemorrhage in conscious rats.
Hypertension (Dallas, Tex. : 1979).
1996 Jan; 27(1):136-43. doi:
10.1161/01.hyp.27.1.136. [PMID: 8591876] - N Nishioka, S Hirai, K Mizuno, S Osada, A Suzuki, K Kosaka, S Ohno. Wortmannin inhibits the activation of MAP kinase following vasopressin V1 receptor stimulation.
FEBS letters.
1995 Dec; 377(3):393-8. doi:
10.1016/0014-5793(95)01382-2. [PMID: 8549762] - N Fujita, S E Ishikawa, S Sasaki, G Fujisawa, K Fushimi, F Marumo, T Saito. Role of water channel AQP-CD in water retention in SIADH and cirrhotic rats.
The American journal of physiology.
1995 Dec; 269(6 Pt 2):F926-31. doi:
10.1152/ajprenal.1995.269.6.f926. [PMID: 8594889] - K Ota, T Kimura, M Inoue, T Funyu, M Shoji, K Sato, M Ohta, T Yamamoto, K Abe. Effects of V1- and V2-vasopressin (AVP) antagonists on the pressor, AVP and atrial natriuretic peptide responses to a hypertonic saline infusion in conscious anephric rats.
European journal of endocrinology.
1995 Jul; 133(1):127-32. doi:
10.1530/eje.0.1330127. [PMID: 7627334] - K Shimizu. Aquaretic effects of the nonpeptide V2 antagonist OPC-31260 in hydropenic humans.
Kidney international.
1995 Jul; 48(1):220-6. doi:
10.1038/ki.1995.287. [PMID: 7564082] - H Okada, H Suzuki, Y Kanno, T Saruta. Effects of novel, nonpeptide vasopressin antagonists on progressive nephrosclerosis in rats.
Journal of cardiovascular pharmacology.
1995 May; 25(5):847-52. doi:
10.1097/00005344-199505000-00023. [PMID: 7630164] - E Ufer, R Postina, V Gorbulev, F Fahrenholz. An extracellular residue determines the agonist specificity of V2 vasopressin receptors.
FEBS letters.
1995 Mar; 362(1):19-23. doi:
10.1016/0014-5793(95)00150-8. [PMID: 7698346] - A Ohnishi, Y Orita, N Takagi, T Fujita, T Toyoki, Y Ihara, Y Yamamura, T Inoue, T Tanaka. Aquaretic effect of a potent, orally active, nonpeptide V2 antagonist in men.
The Journal of pharmacology and experimental therapeutics.
1995 Feb; 272(2):546-51. doi:
NULL. [PMID: 7853167] - M Naitoh, H Suzuki, M Murakami, A Matsumoto, K Arakawa, A Ichihara, H Nakamoto, K Oka, Y Yamamura, T Saruta. Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs.
The American journal of physiology.
1994 Dec; 267(6 Pt 2):H2245-54. doi:
10.1152/ajpheart.1994.267.6.h2245. [PMID: 7810724] - H Okada, H Suzuki, Y Kanno, Y Yamamura, T Saruta. Chronic and selective vasopressin blockade in spontaneously hypertensive rats.
The American journal of physiology.
1994 Dec; 267(6 Pt 2):R1467-71. doi:
10.1152/ajpregu.1994.267.6.r1467. [PMID: 7810754] - Y Fujisawa, A Miyatake, Y Hayashida, Y Aki, S Kimura, T Tamaki, Y Abe. Role of vasopressin on cardiovascular changes during hemorrhage in conscious rats.
The American journal of physiology.
1994 Nov; 267(5 Pt 2):H1713-8. doi:
10.1152/ajpheart.1994.267.5.h1713. [PMID: 7977803] - Y Tsuboi, S Ishikawa, G Fujisawa, K Okada, T Saito. In vivo diuretic effect of a new non-peptide arginine vasopressin antagonist, OPC-31260, in conscious rats.
The Journal of endocrinology.
1994 Nov; 143(2):227-34. doi:
10.1677/joe.0.1430227. [PMID: 7829988] - K Takeuchi, N Yanai, N Takahashi, T Abe, E Tsutsumi, M Obinata, K Abe. Different cellular mechanisms of vasopressin receptor V1 and V2 subtype in vasopressin-induced adenosine 3', 5'-monophosphate formation in an immortalized renal tubule cell line, TKC2.
Biochemical and biophysical research communications.
1994 Jul; 202(2):680-7. doi:
10.1006/bbrc.1994.1984. [PMID: 8048937] - Y Tsuboi, S Ishikawa, G Fujisawa, K Okada, T Saito. Therapeutic efficacy of the non-peptide AVP antagonist OPC-31260 in cirrhotic rats.
Kidney international.
1994 Jul; 46(1):237-44. doi:
10.1038/ki.1994.265. [PMID: 7933842] - T Nakanishi, A Yamauchi, H Nakahama, Y Yamamura, Y Yamada, Y Orita, Y Fujiwara, N Uyeda, Y Takamitsu, M Sugita. Organic osmolytes in rat renal inner medulla are modulated by vasopressin V1 and/or V2 antagonists.
The American journal of physiology.
1994 Jul; 267(1 Pt 2):F146-52. doi:
10.1152/ajprenal.1994.267.1.f146. [PMID: 8048555] - H Okada, H Suzuki, Y Kanno, Y Yamamura, T Saruta. Effects of vasopressin V1 and V2 receptor antagonists on progressive renal failure in rats.
Clinical science (London, England : 1979).
1994 Apr; 86(4):399-404. doi:
10.1042/cs0860399. [PMID: 8168333] - L M Burrell, P A Phillips, J M Stephenson, J Risvanis, C I Johnston. Vasopressin and a nonpeptide antidiuretic hormone receptor antagonist (OPC-31260).
Blood pressure.
1994 Mar; 3(1-2):137-41. doi:
10.3109/08037059409101533. [PMID: 8199714] - T Nakamura, T Sakamaki, T Kurashina, J Hoshino, K Sato, Z Ono, K Murata. Effect of vasopressin V (OPC-21268) and V2 (OPC-31260) antagonists on renal hemodynamics and excretory function.
Life sciences.
1994; 55(4):PL67-72. doi:
10.1016/0024-3205(94)00736-5. [PMID: 8028441] - A Ohnishi, Y Orita, R Okahara, H Fujihara, T Inoue, Y Yamamura, Y Yabuuchi, T Tanaka. Potent aquaretic agent. A novel nonpeptide selective vasopressin 2 antagonist (OPC-31260) in men.
The Journal of clinical investigation.
1993 Dec; 92(6):2653-9. doi:
10.1172/jci116881. [PMID: 8254021] - M Naitoh, H Suzuki, M Murakami, A Matsumoto, A Ichihara, H Nakamoto, Y Yamamura, T Saruta. Arginine vasopressin produces renal vasodilation via V2 receptors in conscious dogs.
The American journal of physiology.
1993 Oct; 265(4 Pt 2):R934-42. doi:
10.1152/ajpregu.1993.265.4.r934. [PMID: 8238468] - A Saigo, Y Takano, T Matsumoto, M Tran, Y Nakayama, R Saito, K Yamada, H Kamiya. Central administration of senktide, a tachykinin NK-3 agonist, has an antidiuretic action by stimulating AVP release in water-loaded rats.
Neuroscience letters.
1993 Sep; 159(1-2):187-90. doi:
10.1016/0304-3940(93)90830-e. [PMID: 7505413]